This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Rossini, P M Articles by Caltagirone, C Search for Related Content PubMed PubMed Citation Articles by Rossini, P M Articles by Caltagirone, C Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB 4-AMINOPYRIDINE Social Bookmarking                         What's this?

Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine

AFaR-Ospedale `San Giovanni Calibita' Fatebenefratelli, Rome, Italy, IRCSS `San Giovanni di Dio' Fatebenefratelli, Brescia, Italy, Neurology, Università Campus Biomedico, Rome, Italy

P Pasqualetti

AFaR-Ospedale `San Giovanni Calibita' Fatebenefratelli, Rome, Italy, IRCSS `San Giovanni di Dio' Fatebenefratelli, Brescia, Italy

C Pozzilli

Dip. Scienze Neurologiche, Università `La Sapienza', Rome, Italy

M G Grasso

IRCSS `S. Lucia', Rome, Italy

E Millefiorini

Dip. Scienze Neurologiche, Università `La Sapienza', Rome, Italy

A Graceffa

IRCSS `S. Lucia', Rome, Italy

G A Carlesimo

IRCSS `S. Lucia', Rome, Italy

G Zibellini

Dept. Research, Sigma-Tau Industries, Pomezia, Italy

C Caltagirone

IRCSS `S. Lucia', Rome, Italy, Clinica Neurologica, Università `Tor Vergata', Rome, Italy

Previous studies suggest that aminopyridine may play a role in the symptomatic treatment of fatigue in multiple sclerosis. Although the mechanism underlying the beneficial effect on fatigue remains unclear, it has been proposed that aminopyridines may help to improve conduction in demyelinated central pathways, implicating both axonal and synaptic mechanisms. The objective of the present study is to determine whether 4-AP decreases daily-living fatigue in progressive multiple sclerosis. The effect of 4-AP on other neurophysiological and neuropsychological parameters was also considered. A `double-blind', randomized, `placebo-controlled', crossover trial was conducted on 54 patients with progressive multiple sclerosis. All patients received treatment with placebo and 32 mg per day of 4-AP, each for 6 months. The main outcome measure was the Fatigue Severity Scale. Secondary measures were EDSS, cognitive functions and neurophysiological parameters. Forty-nine patients (91%) completed the study. Changes in fatigue scores, EDSS and cognitive functions were not significantly different between 4-AP and placebo. However, when patients treated with 4-AP were divided into two groups according to the serum level of 4-AP, a significant effect on fatigue compared with placebo was observed in the `high level' (430 ng/ml) group (P=0.05). Synchronization of motor evoked potentials improved during 4-AP with respect to placebo (P=0.019) and this correlated positively with fatigue reduction (P=0.010). No relevant side effects were observed.

Key Words: multiple sclerosis • aminopyridine • fatigue • demyelination • motor evoked potential

Multiple Sclerosis, Vol. 7, No. 6, 354-358 (2001)
DOI: 10.1177/135245850100700602


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Matta, R. J. Leigh, M. Pugliatti, I. Aiello, and A. Serra Using fast eye movements to study fatigue in multiple sclerosis Neurology, September 8, 2009; 73(10): 798 - 804. [Abstract] [Full Text] [PDF]

				S. Morrow, B Weinstock-Guttman, F. Munschauer, D Hojnacki, and R. Benedict Subjective fatigue is not associated with cognitive impairment in multiple sclerosis: cross-sectional and longitudinal analysis Multiple Sclerosis, August 1, 2009; 15(8): 998 - 1005. [Abstract] [PDF]

				D. Kos, E. Kerckhofs, G. Nagels, M.B. D'hooghe, and S. Ilsbroukx Origin of Fatigue in Multiple Sclerosis: Review of the Literature Neurorehabil Neural Repair, February 1, 2008; 22(1): 91 - 100. [Abstract] [PDF]

				B. Stankoff, E. Waubant, C. Confavreux, G. Edan, M. Debouverie, L. Rumbach, T. Moreau, J. Pelletier, C. Lubetzki, M. Clanet, et al. Modafinil for fatigue in MS: A randomized placebo-controlled double-blind study Neurology, April 12, 2005; 64(7): 1139 - 1143. [Abstract] [Full Text] [PDF]

				H. Crayton, R. A. Heyman, and H. S. Rossman A multimodal approach to managing the symptoms of multiple sclerosis Neurology, December 14, 2004; 63(11_suppl_5): S12 - S18. [Abstract] [Full Text]

				A. Romani, R. Bergamaschi, E. Candeloro, E. Alfonsi, R. Callieco, and V. Cosi Fatigue in multiple sclerosis: multidimensional assessment and response to symptomatic treatment Multiple Sclerosis, August 1, 2004; 10(4): 462 - 468. [Abstract] [PDF]

				C. Mainero, M. Inghilleri, P. Pantano, A. Conte, D. Lenzi, V. Frasca, L. Bozzao, and C. Pozzilli Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine Neurology, June 8, 2004; 62(11): 2044 - 2050. [Abstract] [Full Text] [PDF]